Please login to the form below

Not currently logged in

Excellence in Managing Established Products

Sponsored by

Back to Results


Striving for Better Patient Outcomes in Psoriasis with Cosentyx (secukinumab)

by Novartis UK with support from 90TEN

Summary of work

In March 2018, patients and HCPs were ‘settling’ for sub-par psoriasis treatments that did not fully clear patients’ skin, despite such treatments being available. Visible, painful skin lesions profoundly affect patients’ lives, and incomplete treatment still leaves sufferers carrying this burden. In addition, co-morbid conditions related to psoriasis were often being treated by completely separate teams, leading to disjointed care and suboptimal outcomes.

Novartis aimed to change this, and help psoriasis patients achieve better quality of life through the right treatments and holistic care.

By June 2019, a wealth of educational content had been delivered to various audiences involved in the psoriasis patient journey, with the aim of informing the dermatology community how Cosentyx can offer superior outcomes and better quality of life to patients. Messaging emphasised benefits of treating the complete patient, treating early, and how optimal results can be obtained in biologic-naïve patients. Delegate feedback indicated that these messages were clearly understood, and that appropriate changes to clinical practice would be made.

Cosentyx was the original IL-17A inhibitor on the market and continues to thrive in a crowded market of competitors, including biosimilars, four years after launch.

Judges' comments

Novartis and 90TEN’s project started with a stakeholder interview and it had a good range of measures. It was all about the profound impact on patients, the personas were good and there was good evidence of changing clinical practices.


‘No Compromise For Her’ Creative Educational Campaign - by UCB Pharma S.A. with support from Carling Communications London

Highly commended

Octasa Sales and Marketing Campaign - by Tillotts Pharma UK


You Go Beyond - by Align Technology with support from Page & Page We all go beyond

The SPIRIVA® RESPIMAT® Success Story - by Boehringer Ingelheim with support from Aptus Health International

Striving for Better Patient Outcomes in Psoriasis with Cosentyx (secukinumab) - by Novartis UK with support from 90TEN

Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022